ELP3: The Protein That May Hold the Key to Cancer Treatment (G55140)

Target Name: ELP3

NCBI ID: G55140

ELP3

ELP3: The Protein That May Hold the Key to Cancer Treatment

The discovery of new proteins with unique functions has always been a driving force in the field of science. One such protein is ELP3 (Elongator complex protein 3), a protein that has been identified as a potential drug target or biomarker for cancer treatment. In this article, we will explore the history of ELP3, its functions, potential uses in cancer treatment, and current research efforts to develop it as a drug.

History of ELP3

ELP3 was first identified in the 1990s as a protein that was expressed in a wide range of tissues, including the brain, heart, liver, and muscle. The protein was named based on its ability to extend the length of its sequence in response to stress, such as the formation of new bonds.

While ELP3 was first identified in the lab, there is evidence to suggest that it has been involved in many different biological processes throughout the body. For example, studies have shown that ELP3 is involved in the regulation of cell growth, differentiation, and survival. It has also been shown to play a role in the development and progression of a variety of diseases, including cancer.

Potential Functions as a Drug Target

The potential use of ELP3 as a drug target or biomarker is based on its involvement in a variety of cellular processes that are associated with cancer. One of the key functions of ELP3 is its role in cell signaling, particularly in the regulation of cell growth and differentiation. Studies have shown that ELP3 plays a negative role in the development of cancer by promoting the growth and survival of cancer cells.

In addition to its role in cell signaling, ELP3 has also been shown to play a role in the regulation of cellular processes that are critical for cancer development, such as the production and destruction of DNA. Studies have shown that ELP3 helps to promote the accumulation of DNA repair errors in cancer cells, which can lead to the development of cancer.

Potential Use as a Biomarker

The potential use of ELP3 as a biomarker for cancer diagnosis and treatment is based on its expression and levels in cancer cells. Studies have shown that ELP3 is often expressed in higher levels in cancer cells compared to healthy cells. This makes it an attractive potential biomarker for cancer diagnosis and treatment.

In addition to its potential use as a biomarker, ELP3 has also been shown to be a potential drug target for cancer treatment. By inhibiting the activity of ELP3, researchers may be able to inhibit the growth and survival of cancer cells. This is an attractive potential mechanism for cancer treatment, as it allows for the development of targeted therapies that can be more effective and less invasive than traditional cancer treatments.

Current Research Efforts

While there is still much to be learned about the functions of ELP3, research efforts are underway to develop it as a potential drug target or biomarker for cancer treatment. One approach being used is to investigate the effects of inhibiting the activity of ELP3 on cancer cell growth and survival.

Another approach is to use ELP3 as a biomarker to monitor the effectiveness of cancer treatments. This could involve the use of techniques such as ELISAs (Enhanced Luciferase Assays) or western blotting to monitor the levels of ELP3 in cancer cells before and after treatment, as well as the levels in healthy cells.

Conclusion

In conclusion, ELP3 is a protein that has been identified as a potential drug target or biomarker for cancer treatment. Its functions in cell signaling and the regulation of cellular processes are consistent with its potential as a cancer treatment. While more research is needed to fully understand its potential, the development of ELP3 as a potential drug target or biomarker for cancer treatment is an exciting area of research that has the potential to lead to new and more effective treatments for cancer.

Protein Name: Elongator Acetyltransferase Complex Subunit 3

Functions: Catalytic tRNA acetyltransferase subunit of the elongator complex which is required for multiple tRNA modifications, including mcm5U (5-methoxycarbonylmethyl uridine), mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine), and ncm5U (5-carbamoylmethyl uridine) (PubMed:29415125). In the elongator complex, acts as a tRNA uridine(34) acetyltransferase by mediating formation of carboxymethyluridine in the wobble base at position 34 in tRNAs (By similarity). May also act as a protein lysine acetyltransferase by mediating acetylation of target proteins; such activity is however unclear in vivo and recent evidences suggest that ELP3 primarily acts as a tRNA acetyltransferase (PubMed:29415125). Involved in neurogenesis: regulates the migration and branching of projection neurons in the developing cerebral cortex, through a process depending on alpha-tubulin acetylation (PubMed:19185337). Required for acetylation of GJA1 in the developing cerebral cortex (By similarity)

The "ELP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets